KW 6356

Drug Profile

KW 6356

Alternative Names: KW-6356

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Kyowa Hakko Kirin
  • Class Antiparkinsonians
  • Mechanism of Action Adenosine A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 01 Sep 2016 Phase-II clinical trials in Parkinson's disease in Japan (PO) (JapicCTI163395)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top